Recordati Puts Ownership Uncertainty Aside With Healthy Revenue Rise

31 Jul 2024

The Milan-based drugmaker, which is reportedly attracting attention from private equity firms, has put in a strong performance in the first half of the year, helped by a strong showing for its rare disease franchises.

Koremans_ Rob — Rob Koremans • Source: Recordati

Majority shareholder CVC Capital Partners may be weighing up the sale of its stake in Recordati SpA but it is business as usual at the Italian pharmaceutical company which has posted a decent set of financials for the first half of 2024.

CVC, which paid around €3.03bn for a 51.8% stake of the company seven years ago, has reportedly enlisted JP Morgan and Goldman Sachs to explore strategic alternatives for its holding, according to Bloomberg. Citing people familiar with the matter, the news agency stated earlier this year that the options range from a complete sale to merging Recordati with another healthcare business

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

06 May 2025

• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

05 May 2025

• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Lilly’s Ricks Urges Trump To Pick Tax Incentives Over Tariffs

02 May 2025

• By Alaric DeArment

On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.

Transient FY26 For Syngene But Momentum In China +1 Projects

02 May 2025

• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.